Cilostazol in the management of atherosclerosis

Area of Science:

• Cardiovascular Medicine
• Pharmacology

Background:

• Atherosclerosis is a leading cause of mortality and disability, particularly in Western countries, affecting cerebral, coronary, and peripheral arteries.
• Key mechanisms include inflammation, platelet activation, endothelial damage, smooth muscle cell proliferation/apoptosis imbalance, and oxidative stress.
• Current antithrombotic drugs, primarily antiplatelet agents like aspirin and clopidogrel, carry bleeding risks, necessitating novel therapeutic strategies.

Purpose of the Study:

• To review the pharmacological properties of cilostazol, a phosphodiesterase inhibitor.
• To evaluate the efficacy and safety of cilostazol in managing atherothrombotic vascular diseases.
• To highlight cilostazol's potential as an alternative antiplatelet therapy with a favorable bleeding profile.

Main Methods:

• Review of existing literature on cilostazol's pharmacology and clinical applications.
• Analysis of studies investigating cilostazol's antiplatelet and vasodilator effects.
• Comparison of cilostazol's safety profile, particularly bleeding complications, with other antiplatelet agents.

Main Results:

• Cilostazol exhibits significant antiplatelet and vasodilator properties.
• Clinical studies indicate cilostazol is effective in managing atherothrombotic vascular diseases.
• Cilostazol demonstrates a low rate of bleeding complications compared to traditional antiplatelet therapies.

Conclusions:

• Cilostazol is a promising therapeutic option for atherothrombotic vascular diseases.
• Its dual action (antiplatelet and vasodilator) combined with a favorable safety profile makes it valuable.
• Further research and clinical integration of cilostazol are warranted for optimizing patient outcomes.